These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32956819)

  • 21. Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis.
    Freyer CW; Babushok DV; Frey NV; Gill SI; Loren AW; Luger SM; Maity A; Martin ME; Plastaras JP; Porter DL; Hexner EO
    Transplant Cell Ther; 2022 Sep; 28(9):590-596. PubMed ID: 35772699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
    Piñana JL; Valcárcel D; Martino R; Barba P; Moreno E; Sureda A; Vega M; Delgado J; Briones J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):21-9. PubMed ID: 19135939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using
    Mei M; Palmer J; Tsai NN; Simpson J; O'Hearn J; Stein A; Forman S; Spielberger R; Cai JL; Htut M; Nakamura R; Al Malki MM; Herrera A; Wong J; Nademanee A
    Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e268-e276. PubMed ID: 37301631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
    Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
    Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.
    Dreger P; Sureda A; Ahn KW; Eapen M; Litovich C; Finel H; Boumendil A; Gopal A; Herrera AF; Schmid C; Diez-Martin JL; Fuchs E; Bolaños-Meade J; Gooptu M; Al Malki MM; Castagna L; Ciurea SO; Dominietto A; Blaise D; Ciceri F; Tischer J; Corradini P; Montoto S; Robinson S; Gülbas Z; Hamadani M
    Blood Adv; 2019 Feb; 3(3):360-369. PubMed ID: 30723110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is Treosulfan-Based Conditioning Attractive as a Reduced-Intensity Conditioning Regimen in Korea?
    Kim SH; Ji YS; Yun J; Choi SH; Lim SH; Kim CK; Park SK
    J Korean Med Sci; 2023 Sep; 38(36):e281. PubMed ID: 37698206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of Fludarabine, Melphalan and Total Body Irradiation as a Reduced Intensity Conditioning Regimen in Matched Donor Allogeneic Peripheral Blood Stem Cell Transplantation.
    Modi D; Chi J; Kim S; Deol A; Ayash L; Ratanatharathorn V; Uberti JP
    Transplant Cell Ther; 2021 Aug; 27(8):665.e1-665.e7. PubMed ID: 33991722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
    Scordo M; Wang TP; Ahn KW; Chen Y; Ahmed S; Awan FT; Beitinjaneh A; Chen A; Chow VA; Dholaria B; Epperla N; Farooq U; Ghosh N; Grover N; Hamad N; Hildebrandt GC; Holmberg L; Hong S; Inwards DJ; Jimenez-Jimenez A; Karmali R; Kenkre VP; Khimani F; Klyuchnikov E; Krem MM; Munshi PN; Nieto Y; Prestidge T; Ramakrishnan Geethakumari P; Rezvani AR; Riedell PA; Seo S; Shah NN; Solh M; Yared JA; Kharfan-Dabaja MA; Herrera A; Hamadani M; Sauter CS
    JAMA Oncol; 2021 Jul; 7(7):993-1003. PubMed ID: 33956047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
    Modi D; Singh V; Kim S; Ayash L; Deol A; Ratanatharathorn V; Uberti JP
    Ann Hematol; 2021 Apr; 100(4):969-978. PubMed ID: 33594448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
    Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
    Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.
    Lewis C; Kim HT; Roeker LE; Cutler C; Koreth J; Nikiforow S; Armand P; Gootpu M; Romee R; Glotzbecker B; Nageshwar P; Antin JH; Alyea EP; Richardson P; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):529-539. PubMed ID: 31678537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.
    Zhou Z; Nath R; Cerny J; Wang HL; Zhang MJ; Abdel-Azim H; Agrawal V; Ahmed G; Al-Homsi AS; Aljurf M; Alkhateeb HB; Assal A; Bacher U; Bajel A; Bashir Q; Battiwalla M; Bhatt VR; Byrne M; Cahn JY; Cairo M; Choe H; Copelan E; Cutler C; Damlaj MB; DeFilipp Z; De Lima M; Diaz MA; Farhadfar N; Foran J; Freytes CO; Gerds AT; Gergis U; Grunwald MR; Gul Z; Hamadani M; Hashmi S; Hertzberg M; Hildebrandt GC; Hossain N; Inamoto Y; Isola L; Jain T; Kamble RT; Khan MW; Kharfan-Dabaja MA; Kebriaei P; Kekre N; Khera N; Lazarus HM; Liesveld JL; Litzow M; Liu H; Marks DI; Martino R; Mathews V; Mishra A; Murthy HS; Nagler A; Nakamura R; Nathan S; Nishihori T; Olin R; Olsson RF; Palmisiano N; Patel SS; Patnaik MM; Pawarode A; Perales MA; Politikos I; Popat U; Rizzieri D; Sandmaier BM; Savani BN; Seo S; Shah NN; Uy GL; Valcárcel D; Verdonck LF; Waller EK; Wang Y; Weisdorf D; Wirk B; Wong E; Yared JA; Saber W
    Blood Adv; 2020 Jul; 4(13):3180-3190. PubMed ID: 32663298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia with a Busulfan, Fludarabine, and Melphalan Regimen: JPLSG JMML-11.
    Sakashita K; Yoshida N; Muramatsu H; Ohtsuka Y; Watanabe K; Yabe M; Kakuda H; Honda Y; Watanabe T; Haba M; Ohmori S; Matsuda K; Yuza Y; Saito A; Horibe K; Adachi S; Manabe A
    Transplant Cell Ther; 2024 Jan; 30(1):105.e1-105.e10. PubMed ID: 37806448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
    Bertz H; Illerhaus G; Veelken H; Finke J
    Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.
    Malard F; Cahu X; Clavert A; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Mahe B; Gastinne T; Blin N; Harousseau JL; Moreau P; Miplied N; Le Gouill S; Mohty M
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1698-703. PubMed ID: 21601642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning.
    Joseph J; Srour SA; Milton DR; Ramdial JL; Saini NY; Olson AL; Bashir Q; Oran B; Alousi AM; Hosing C; Qazilbash MH; Kebriaei P; Shpall EJ; Champlin RE; Popat UR
    Transplant Cell Ther; 2023 Dec; 29(12):770.e1-770.e6. PubMed ID: 37742746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.